Skip to main content
Top
Published in: Respiratory Research 1/2012

Open Access 01-12-2012 | Research

Heterozygosity for E292V in ABCA3, lung function and COPD in 64,000 individuals

Authors: Marie Bækvad-Hansen, Børge G Nordestgaard, Morten Dahl

Published in: Respiratory Research | Issue 1/2012

Login to get access

Abstract

Background

Mutations in ATP-binding-cassette-member A3 (ABCA3) are related to severe chronic lung disease in neonates and children, but frequency of chronic lung disease due to ABCA3 mutations in the general population is unknown. We tested the hypothesis that individuals heterozygous for ABCA3 mutations have reduced lung function and increased risk of COPD in the general population.

Methods

We screened 760 individuals with extreme pulmonary phenotypes and identified three novel (H86Y, A320T, A1086D) and four previously described mutations (E292V, P766S, S1262G, R1474W) in the ABCA3 gene. We genotyped the entire Copenhagen City Heart study (n = 10,604) to assess the clinical importance of these mutations. To validate our findings we genotyped an additional 54,395 individuals from the Copenhagen General Population Study.

Results

In the Copenhagen City Heart Study individuals heterozygous for E292V had 5% reduced FEV1 % predicted compared with noncarriers (t-test: p = 0.008), and an increased odds ratio for COPD of 1.9 (95% CI: 1.1-3.1). In contrast, the A1086D mutation was associated with increased FEV1 % predicted (p = 0.03). None of the other ABCA3 mutations associated with lung function or COPD risk in the Copenhagen City Heart Study. In the larger Copenhagen General Population Study, and in the two studies combined, E292V heterozygotes did not have reduced lung function or increased risk of COPD (p = 0.11-0.98), while this was the case for the positive controls, surfactant protein-B 121ins2 heterozygotes and α 1 -antitrypsin ZZ homozygotes.

Conclusion

Our results indicate that partially reduced ABCA3 activity due to E292V is not a major risk factor for reduced lung function and COPD in the general population. This is an important finding as 1.3% in the Danish population has partially reduced ABCA3 function due to E292V.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dietl P, Liss B, Felder E, Miklavc P, Wirtz H: Lamellar body exocytosis by cell stretch or purigernic stimulation: possible physiological roles, messengers and mechanisms. Cell Physiol Biochem. 2010, 25: 1-12. 10.1159/000272046.PubMedCrossRef Dietl P, Liss B, Felder E, Miklavc P, Wirtz H: Lamellar body exocytosis by cell stretch or purigernic stimulation: possible physiological roles, messengers and mechanisms. Cell Physiol Biochem. 2010, 25: 1-12. 10.1159/000272046.PubMedCrossRef
2.
go back to reference Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA: Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L259-L271. 10.1152/ajplung.00112.2007.PubMedCrossRef Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA: Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L259-L271. 10.1152/ajplung.00112.2007.PubMedCrossRef
3.
go back to reference Whitsett JA, Wert SE, Weaver TE: Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med. 2010, 61: 105-119. 10.1146/annurev.med.60.041807.123500.PubMedPubMedCentralCrossRef Whitsett JA, Wert SE, Weaver TE: Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med. 2010, 61: 105-119. 10.1146/annurev.med.60.041807.123500.PubMedPubMedCentralCrossRef
4.
go back to reference Ban N, Matsumura Y, Sakai H, et al: ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. J Biol Chem. 2007, 282: 9628-9634. 10.1074/jbc.M611767200.PubMedCrossRef Ban N, Matsumura Y, Sakai H, et al: ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. J Biol Chem. 2007, 282: 9628-9634. 10.1074/jbc.M611767200.PubMedCrossRef
5.
go back to reference Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M: ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med. 2004, 350: 1296-1303. 10.1056/NEJMoa032178.PubMedCrossRef Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M: ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med. 2004, 350: 1296-1303. 10.1056/NEJMoa032178.PubMedCrossRef
6.
go back to reference Matsumura Y, Ban N, Inagaki N: Aberrant catalytic cycle and impaired lipid transport into intracellular vesicles in ABCA3 mutants associated with nonfatal pediatric interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2008, 295: L698-L707. 10.1152/ajplung.90352.2008.PubMedCrossRef Matsumura Y, Ban N, Inagaki N: Aberrant catalytic cycle and impaired lipid transport into intracellular vesicles in ABCA3 mutants associated with nonfatal pediatric interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2008, 295: L698-L707. 10.1152/ajplung.90352.2008.PubMedCrossRef
7.
go back to reference Garmany TH, Wambach JA, Heins HB, et al: Population and disease-based prevalence of the common mutations associated with surfactant deficiency. Pediatr Res. 2008, 63: 645-649. 10.1203/PDR.0b013e31816fdbeb.PubMedPubMedCentralCrossRef Garmany TH, Wambach JA, Heins HB, et al: Population and disease-based prevalence of the common mutations associated with surfactant deficiency. Pediatr Res. 2008, 63: 645-649. 10.1203/PDR.0b013e31816fdbeb.PubMedPubMedCentralCrossRef
8.
go back to reference Bullard JE, Wert SE, Whitsett JA, Dean M, Nogee LM: ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med. 2005, 172: 1026-1031. 10.1164/rccm.200503-504OC.PubMedPubMedCentralCrossRef Bullard JE, Wert SE, Whitsett JA, Dean M, Nogee LM: ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med. 2005, 172: 1026-1031. 10.1164/rccm.200503-504OC.PubMedPubMedCentralCrossRef
9.
go back to reference Somaschini M, Nogee LM, Sassi I, et al: Unexplained neonatal respiratory distress due to congenital surfactant deficiency. J Pediatr. 2007, 150: 649-653. 10.1016/j.jpeds.2007.03.008.PubMedCrossRef Somaschini M, Nogee LM, Sassi I, et al: Unexplained neonatal respiratory distress due to congenital surfactant deficiency. J Pediatr. 2007, 150: 649-653. 10.1016/j.jpeds.2007.03.008.PubMedCrossRef
10.
go back to reference Doan ML, Guillerman RP, Dishop MK, et al: Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax. 2008, 63: 366-373. 10.1136/thx.2007.083766.PubMedCrossRef Doan ML, Guillerman RP, Dishop MK, et al: Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax. 2008, 63: 366-373. 10.1136/thx.2007.083766.PubMedCrossRef
11.
go back to reference Besnard V, Matsuzaki Y, Clark J, et al: Conditional deletion of ABCA3 in alveolar type II cells alters surfactant homeostasis in newborn and adult mice. Am J Physiol Lung Cell Mol Physiol. 2010, 298: L646-L659. 10.1152/ajplung.00409.2009.PubMedPubMedCentralCrossRef Besnard V, Matsuzaki Y, Clark J, et al: Conditional deletion of ABCA3 in alveolar type II cells alters surfactant homeostasis in newborn and adult mice. Am J Physiol Lung Cell Mol Physiol. 2010, 298: L646-L659. 10.1152/ajplung.00409.2009.PubMedPubMedCentralCrossRef
12.
go back to reference Baekvad-Hansen M, Dahl M, Tybjaerg-Hansen A, Nordestgaard BG: Surfactant protein-B 121ins2 heterozygosity, reduced pulmonary function, and chronic obstructive pulmonary disease in smokers. Am J Respir Crit Care Med. 2010, 181: 17-20. 10.1164/rccm.200906-0963OC.PubMedCrossRef Baekvad-Hansen M, Dahl M, Tybjaerg-Hansen A, Nordestgaard BG: Surfactant protein-B 121ins2 heterozygosity, reduced pulmonary function, and chronic obstructive pulmonary disease in smokers. Am J Respir Crit Care Med. 2010, 181: 17-20. 10.1164/rccm.200906-0963OC.PubMedCrossRef
13.
go back to reference Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG: Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. Ann Intern Med. 2002, 136: 270-279.PubMedCrossRef Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG: Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. Ann Intern Med. 2002, 136: 270-279.PubMedCrossRef
14.
go back to reference Baekvad-Hansen M, Nordestgaard BG, Dahl M: Surfactant protein B polymorphisms, pulmonary function and COPD in 10,231 individuals. Eur Respir J. 2011, 37: 791-799. 10.1183/09031936.00026410.PubMedCrossRef Baekvad-Hansen M, Nordestgaard BG, Dahl M: Surfactant protein B polymorphisms, pulmonary function and COPD in 10,231 individuals. Eur Respir J. 2011, 37: 791-799. 10.1183/09031936.00026410.PubMedCrossRef
15.
go back to reference Dahl M, Vestbo J, Zacho J, Lange P, Tybjaerg-Hansen A, Nordestgaard BG: C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax. 2011, 66: 197-204. 10.1136/thx.2009.131193.PubMedCrossRef Dahl M, Vestbo J, Zacho J, Lange P, Tybjaerg-Hansen A, Nordestgaard BG: C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax. 2011, 66: 197-204. 10.1136/thx.2009.131193.PubMedCrossRef
16.
go back to reference From the Global Strategy for the Diagnosis, Management and Prevention of COPD: Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2011, Available from: http://www.goldcopd.org/ From the Global Strategy for the Diagnosis, Management and Prevention of COPD: Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2011, Available from: http://​www.​goldcopd.​org/​
17.
go back to reference Baekvad-Hansen M, Nordestgaard BG, Tybjaerg-Hansen A, Dahl M: Two novel mutations in surfactant protein-C, lung function and obstructive lung disease. Respir Med. 2010, 104: 418-425. 10.1016/j.rmed.2009.10.012.PubMedCrossRef Baekvad-Hansen M, Nordestgaard BG, Tybjaerg-Hansen A, Dahl M: Two novel mutations in surfactant protein-C, lung function and obstructive lung disease. Respir Med. 2010, 104: 418-425. 10.1016/j.rmed.2009.10.012.PubMedCrossRef
18.
go back to reference Reed GH, Wittwer CT: Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem. 2004, 50: 1748-1754. 10.1373/clinchem.2003.029751.PubMedCrossRef Reed GH, Wittwer CT: Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem. 2004, 50: 1748-1754. 10.1373/clinchem.2003.029751.PubMedCrossRef
19.
go back to reference Matsumura Y, Ban N, Ueda K, Inagaki N: Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency. J Biol Chem. 2006, 281: 34503-34514. 10.1074/jbc.M600071200.PubMedCrossRef Matsumura Y, Ban N, Ueda K, Inagaki N: Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency. J Biol Chem. 2006, 281: 34503-34514. 10.1074/jbc.M600071200.PubMedCrossRef
20.
go back to reference Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT-algorithm. Nat Protoc. 2009, 4: 1073-1082. 10.1038/nprot.2009.86.PubMedCrossRef Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT-algorithm. Nat Protoc. 2009, 4: 1073-1082. 10.1038/nprot.2009.86.PubMedCrossRef
22.
go back to reference Thomsen M, Nordestgaard BG, Sethi AA, Tybjaerg-Hansen A, Dahl M: beta(2) -Adrenergic Receptor polymorphisms, asthma and COPD: two large population-based studies. Eur Respir J. 2012, 39: 558-566. 10.1183/09031936.00023511.PubMedCrossRef Thomsen M, Nordestgaard BG, Sethi AA, Tybjaerg-Hansen A, Dahl M: beta(2) -Adrenergic Receptor polymorphisms, asthma and COPD: two large population-based studies. Eur Respir J. 2012, 39: 558-566. 10.1183/09031936.00023511.PubMedCrossRef
23.
go back to reference Stenger PC, Alonso C, Zasadzinski JA, Waring AJ, Jung CL, Pinkerton KE: Environmental tobacco smoke effects on lung surfactant film organization. Biochim Biophys Acta. 2009, 1788: 358-370. 10.1016/j.bbamem.2008.11.021.PubMedPubMedCentralCrossRef Stenger PC, Alonso C, Zasadzinski JA, Waring AJ, Jung CL, Pinkerton KE: Environmental tobacco smoke effects on lung surfactant film organization. Biochim Biophys Acta. 2009, 1788: 358-370. 10.1016/j.bbamem.2008.11.021.PubMedPubMedCentralCrossRef
24.
go back to reference Bullard JE, Nogee LM, et al: Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation. Pediatr Res. 2007, 62: 176-179. 10.1203/PDR.0b013e3180a72588.PubMedCrossRef Bullard JE, Nogee LM, et al: Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation. Pediatr Res. 2007, 62: 176-179. 10.1203/PDR.0b013e3180a72588.PubMedCrossRef
25.
go back to reference Crossno PF, Polosukhin W, Blackwell TS, et al: Identification of early interstitial lung disease in an individual with genetic variations in ABCA3 and SFTPC. Chest. 2010, 137: 969-973. 10.1378/chest.09-0790.PubMedPubMedCentralCrossRef Crossno PF, Polosukhin W, Blackwell TS, et al: Identification of early interstitial lung disease in an individual with genetic variations in ABCA3 and SFTPC. Chest. 2010, 137: 969-973. 10.1378/chest.09-0790.PubMedPubMedCentralCrossRef
26.
go back to reference Gower WA, Wert SE, Ginsberg JS, Golan A, Whitsett JA, Nogee LM: Fatal familial lung disease caused by ABCA3 deficiency without identified ABCA3 mutations. J Pediatr. 2010, 157: 62-68. 10.1016/j.jpeds.2010.01.010.PubMedCrossRef Gower WA, Wert SE, Ginsberg JS, Golan A, Whitsett JA, Nogee LM: Fatal familial lung disease caused by ABCA3 deficiency without identified ABCA3 mutations. J Pediatr. 2010, 157: 62-68. 10.1016/j.jpeds.2010.01.010.PubMedCrossRef
27.
go back to reference Cheong N, Madesh M, Gonzales LW, et al: Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J Biol Chem. 2006, 281: 9791-9800.PubMedCrossRef Cheong N, Madesh M, Gonzales LW, et al: Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J Biol Chem. 2006, 281: 9791-9800.PubMedCrossRef
28.
go back to reference Weichert N, Kaltenborn E, Hector A, et al: Some ABCA3 mutations elevate ER stress and initiate apoptosis of lung epithelial cells. Respir Res. 2011, 12: 4-10.1186/1465-9921-12-4.PubMedPubMedCentralCrossRef Weichert N, Kaltenborn E, Hector A, et al: Some ABCA3 mutations elevate ER stress and initiate apoptosis of lung epithelial cells. Respir Res. 2011, 12: 4-10.1186/1465-9921-12-4.PubMedPubMedCentralCrossRef
29.
go back to reference Zhao CZ, Fang XC, Wang D, Tang FD, Wang XD: Involvement of type II pneumocytes in the pathogenesis of COPD. Respir Med. 2010, 104: 1391-1395. 10.1016/j.rmed.2010.06.018.PubMedCrossRef Zhao CZ, Fang XC, Wang D, Tang FD, Wang XD: Involvement of type II pneumocytes in the pathogenesis of COPD. Respir Med. 2010, 104: 1391-1395. 10.1016/j.rmed.2010.06.018.PubMedCrossRef
30.
go back to reference Mazur W, Toljamo T, Ohlmeier S, et al: Elevation of surfactant protein A in plasma and sputum in cigarette smokers. Eur Respir J. 2011, 38: 277-284. 10.1183/09031936.00110510.PubMedCrossRef Mazur W, Toljamo T, Ohlmeier S, et al: Elevation of surfactant protein A in plasma and sputum in cigarette smokers. Eur Respir J. 2011, 38: 277-284. 10.1183/09031936.00110510.PubMedCrossRef
31.
go back to reference Foreman MG, Kong X, DeMeo DL, et al: Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2011, 44: 316-322. 10.1165/rcmb.2009-0360OC.PubMedPubMedCentralCrossRef Foreman MG, Kong X, DeMeo DL, et al: Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2011, 44: 316-322. 10.1165/rcmb.2009-0360OC.PubMedPubMedCentralCrossRef
32.
go back to reference Winkler C, Atochina-Vasserman EN, Holz O, et al: Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res. 2011, 12: 29-10.1186/1465-9921-12-29.PubMedPubMedCentralCrossRef Winkler C, Atochina-Vasserman EN, Holz O, et al: Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res. 2011, 12: 29-10.1186/1465-9921-12-29.PubMedPubMedCentralCrossRef
33.
go back to reference Cottin V, Reix P, Khouatra C, Thivolet-Béjui F, Feldmann D, Cordier JF: Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax. 2011, 66: 918-919. 10.1136/thx.2010.151407.PubMedCrossRef Cottin V, Reix P, Khouatra C, Thivolet-Béjui F, Feldmann D, Cordier JF: Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax. 2011, 66: 918-919. 10.1136/thx.2010.151407.PubMedCrossRef
34.
go back to reference Cottin V, Cordier JF: SFTPC Mutations in Patients with familial pulmonary fibrosis: combined with emphysema. Am J Respir Crit Care Med. 2011, 183: 1113-1114.PubMedCrossRef Cottin V, Cordier JF: SFTPC Mutations in Patients with familial pulmonary fibrosis: combined with emphysema. Am J Respir Crit Care Med. 2011, 183: 1113-1114.PubMedCrossRef
35.
go back to reference Thomsen M, Nordestgaard BG, Tybjaerg-Hansen A, Dahl M: Scavenger receptor AI/II truncation, lung function and COPD: a large population-based study. J Intern Med. 2011, 269: 340-348. 10.1111/j.1365-2796.2010.02308.x.PubMedCrossRef Thomsen M, Nordestgaard BG, Tybjaerg-Hansen A, Dahl M: Scavenger receptor AI/II truncation, lung function and COPD: a large population-based study. J Intern Med. 2011, 269: 340-348. 10.1111/j.1365-2796.2010.02308.x.PubMedCrossRef
36.
go back to reference Artigas MS, Wain LV, Repapi E, et al: SpiroMeta Consortium. Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function. Am J Respir Crit Care Med. 2011, 184: 786-795. 10.1164/rccm.201102-0192OC.CrossRef Artigas MS, Wain LV, Repapi E, et al: SpiroMeta Consortium. Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function. Am J Respir Crit Care Med. 2011, 184: 786-795. 10.1164/rccm.201102-0192OC.CrossRef
37.
go back to reference Kim WJ, Hoffman E, Reilly J, et al: Association of COPD candidate genes with computed tomography emphysema and airway phenotypes in severe COPD. Eur Respir J. 2011, 37: 39-43. 10.1183/09031936.00173009.PubMedPubMedCentralCrossRef Kim WJ, Hoffman E, Reilly J, et al: Association of COPD candidate genes with computed tomography emphysema and airway phenotypes in severe COPD. Eur Respir J. 2011, 37: 39-43. 10.1183/09031936.00173009.PubMedPubMedCentralCrossRef
38.
go back to reference Lee J, Nordestgaard BG, Dahl M: EPHX1 polymorphisms, COPD and asthma in 47,000 individuals and in meta-analysis. Eur Respir J. 2011, 37: 18-25. 10.1183/09031936.00012110.PubMedCrossRef Lee J, Nordestgaard BG, Dahl M: EPHX1 polymorphisms, COPD and asthma in 47,000 individuals and in meta-analysis. Eur Respir J. 2011, 37: 18-25. 10.1183/09031936.00012110.PubMedCrossRef
39.
go back to reference Van Durme YM, Eijgelsheim M, Joos GF, et al: Hedgehog-interacting protein is a COPD susceptibility gene: the Rotterdam Study. Eur Respir J. 2010, 36: 89-95. 10.1183/09031936.00129509.PubMedCrossRef Van Durme YM, Eijgelsheim M, Joos GF, et al: Hedgehog-interacting protein is a COPD susceptibility gene: the Rotterdam Study. Eur Respir J. 2010, 36: 89-95. 10.1183/09031936.00129509.PubMedCrossRef
40.
go back to reference van Diemen CC, Postma DS, Siedlinski M, Blokstra A, Smit HA, Boezen HM: Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in two general population-based cohorts. Respir Res. 2011, 12: 57-10.1186/1465-9921-12-57.PubMedPubMedCentralCrossRef van Diemen CC, Postma DS, Siedlinski M, Blokstra A, Smit HA, Boezen HM: Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in two general population-based cohorts. Respir Res. 2011, 12: 57-10.1186/1465-9921-12-57.PubMedPubMedCentralCrossRef
Metadata
Title
Heterozygosity for E292V in ABCA3, lung function and COPD in 64,000 individuals
Authors
Marie Bækvad-Hansen
Børge G Nordestgaard
Morten Dahl
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2012
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-13-67

Other articles of this Issue 1/2012

Respiratory Research 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine